×

Innovest Global, Inc. Announces LOI Acquiring 20% Stake In StemVax, LLC, Entering Into Cancer Vaccine Market - Spotlight Growth

Sacramento, CA , March 21, 2018 (GLOBE NEWSWIRE) -- A new report has been published on Innovest Global, Inc. (OTC PINK: IVST). Innovest Global, Inc. is a diversified holding company that focuses on acquiring niche, high-growth businesses that are capable of generating significant annual revenue. The company’s planned subsidiaries operate across telehealth, biotech, commercial energy, business-to-business distribution, national call center and auto sales.

The report provides an overview of Innovest Global, Inc., its subsidiaries, financials, industry analysis and more. The content also covers brain and central nervous system (CNS) cancers and associated statistics.

ABTA: Forecasts 80,000 New Cases of Primary Brain Tumors This Year

Brain cancers seem to not receive the same level of attention and awareness as other forms of the disease. However, in July 2017, Arizona Senator John McCain announced that he had been diagnosed with an aggressive form of brain cancer, glioblastoma. Glioblastomas are the most common form of brain cancer in adults today.

“Glioblastoma can be difficult to treat. Average survival for malignant glioblastoma tends to be about 14 months with treatment,” says Dr. Sanjay Gupta, a practicing neurosurgeon.

As first-line treatments continue to focus on chemotherapy and radiation, medical professionals are increasingly searching for more advanced methods to treat these forms of cancer.

"The brain tumor community is very united in our quest for finding better treatments for our patients, and I think the progress will come through clearly planned and orchestrated clinical trials, looking at both approaches, immunotherapies and appropriate uses of targeted therapies, which will go and attack the genes that drive a particular tumor," says Dr. Manmeet Ahluwalia, a brain tumor oncologist and director of the brain metastasis program at the Cleveland Clinic in Ohio.

According to the American Brain Tumor Association, an estimated 80,000 new cases of primary brain tumors will be diagnosed this year. Another 17,000 people are estimated to lose their battle with a primary brain or CNS tumor this year.

According to GBI Research, global revenues for the cancer vaccine market are forecast to grow from $2.5 billion in 2015 to $7.5 billion in 2022, which represents a compound annual growth rate (CAGR) of 16.93%.

Innovest Signs LOI to Acquire 20% Stake in StemVax, LLC, a Biotech Company Working On Brain Cancer Vaccine

Innovest Global recently announced that it has signed a Letter of Intent to acquire a 20% stake in StemVax, LLC, a biotechnology company that is currently developing a brain cancer vaccine.

The StemVax Glioblast (SVX-GB) cancer vaccine is being designed and formulated to help restore a patient’s immune system in order to fight off existing cancer cells within the body.

Adding to the excitement of the deal is the fact that Innovest Global’s very own Dr. Dwain Morris-Irvin is the founder and CEO of StemVax, LLC. Dr. Dwain is the CEO of Innovest’s new Biotechnology & Health Sciences Division.

“Innovest is uniquely equipped to provide immeasurably important elements to StemVax that kick things off for StemVax and dramatically improve its potential for success. This is true for other technologies we will encounter, as well. The best way I can show future scientists how Innovest can serve their mission, is to lead by example with my own company,” said Dr. Morris-Irvin. “Dan Martin (Innovest Global CEO) and I have been planning the business model for this division since 2017. It’s unique and will serve both technologists and Innovest well.”

Aside from biotechnology, Innovest also recently announced that its Innovest Energy Group has signed a Letter of Intent to acquire an energy business that is producing annual revenues of $1.2 million. The energy procurement acquisition target will provide the Energy Division with new technologies and synergies.

Once the energy acquisition is completed, management estimates baseline quarterly revenues of $800,000. The Energy Division alone will have more than 300 commercial and industrial clients and puts Innovest Global in perfect position while the company gets started on developing its Biotechnology & Health Sciences Division.

Management continues to vet PCAOB auditors to be engaged with the company and assist with auditing the financials. This is in addition to the fact that the company’s corporate counsel is an official OTCQX sponsor, which positions the company to continue pursuing uplisting endeavors that have been laid out in previous press releases.

For more information on Innovest Global, Inc., please visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/03/20/this-company-is-working-on-a-brain-cancer-vaccine-that-would-help-fight-against-same-tumor-type-as-senator-john-mccains/

SpotlightGrowth.com is a digital hub for micro-caps, small-caps, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small cap companies.

Disclaimer:

Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.

This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/

Contact: Matt Rego 9165257147 mrego@spotlightgrowth.com

Source: Spotlight Growth